332 related articles for article (PubMed ID: 27121206)
1. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
[TBL] [Abstract][Full Text] [Related]
2. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
[TBL] [Abstract][Full Text] [Related]
3. Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma.
Shiraishi H; Fujiwara Y; Kakuya T; Tsuta K; Motoi N; Miura N; Watabe Y; Watanabe SI; Noro R; Nagashima K; Huang W; Yamada T; Asamura H; Ohe Y; Honda K
Biomark Med; 2017 Sep; 11(9):721-731. PubMed ID: 28658966
[TBL] [Abstract][Full Text] [Related]
4. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
Xie J; Zhang X; Hu S; Peng WD; Xu B; Li Y; Zhang SJ; Li Q; Li C
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2231-2239. PubMed ID: 32533405
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
7. Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.
Noro R; Honda K; Tsuta K; Ishii G; Maeshima AM; Miura N; Furuta K; Shibata T; Tsuda H; Ochiai A; Sakuma T; Nishijima N; Gemma A; Asamura H; Nagai K; Yamada T
Ann Oncol; 2013 Oct; 24(10):2594-2600. PubMed ID: 23899839
[TBL] [Abstract][Full Text] [Related]
8. Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial.
Bennouna J; Senellart H; Hiret S; Vaissiere N; Douillard JY
Lung Cancer; 2011 Oct; 74(1):30-4. PubMed ID: 21371774
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C.
Chang TH; Tsai MF; Gow CH; Wu SG; Liu YN; Chang YL; Yu SL; Tsai HC; Lin SW; Chen YW; Kuo PY; Yang PC; Shih JY
Cancer Lett; 2017 Aug; 402():190-202. PubMed ID: 28610956
[TBL] [Abstract][Full Text] [Related]
10. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
Heon S; Johnson BE
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
[TBL] [Abstract][Full Text] [Related]
12. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
14. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.
Reiman T; Lai R; Veillard AS; Paris E; Soria JC; Rosell R; Taron M; Graziano S; Kratzke R; Seymour L; Shepherd FA; Pignon JP; Sève P
Ann Oncol; 2012 Jan; 23(1):86-93. PubMed ID: 21471564
[TBL] [Abstract][Full Text] [Related]
15. Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.
Graziano SL; Lacas B; Vollmer R; Kratzke R; Popper H; Filipits M; Seymour L; Shepherd FA; Rosell R; Veillard AS; Taron M; Pignon JP
Lung Cancer; 2013 Oct; 82(1):149-55. PubMed ID: 23920379
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.
Vansteenkiste JF; Cho BC; Vanakesa T; De Pas T; Zielinski M; Kim MS; Jassem J; Yoshimura M; Dahabreh J; Nakayama H; Havel L; Kondo H; Mitsudomi T; Zarogoulidis K; Gladkov OA; Udud K; Tada H; Hoffman H; Bugge A; Taylor P; Gonzalez EE; Liao ML; He J; Pujol JL; Louahed J; Debois M; Brichard V; Debruyne C; Therasse P; Altorki N
Lancet Oncol; 2016 Jun; 17(6):822-835. PubMed ID: 27132212
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
18. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
19. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB
Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
